WallStSmart

InnovAge Holding Corp (INNV)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 6708% more annual revenue ($67.38B vs $989.71M). MRK leads profitability with a 3.6% profit margin vs -0.3%. MRK earns a higher WallStSmart Score of 44/100 (D).

INNV

Avoid

26

out of 100

Grade: F

Growth: 6.0Profit: 3.5Value: 4.0Quality: 6.5
Piotroski: 4/9Altman Z: 2.48

MRK

Hold

44

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INNVSignificantly Overvalued (-19.6%)

Margin of Safety

-19.6%

Fair Value

$6.84

Current Price

$8.85

$2.01 premium

UndervaluedFair: $6.84Overvalued
MRKSignificantly Overvalued (-76.6%)

Margin of Safety

-76.6%

Fair Value

$84.66

Current Price

$144.70

$60.04 premium

UndervaluedFair: $84.66Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INNV1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
18.3%8/10

18.3% revenue growth

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$368.89B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
41.2%10/10

Strong operational efficiency at 41.2%

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

INNV4 concerns · Avg: 2.0/10
Market CapQuality
$1.30B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-9.7%2/10

ROE of -9.7% — below average capital efficiency

EPS GrowthGrowth
-87.8%2/10

Earnings declined 87.8%

Profit MarginProfitability
-0.3%1/10

Currently unprofitable

MRK4 concerns · Avg: 3.5/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : INNV

The strongest argument for INNV centers on Revenue Growth. Revenue growth of 18.3% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : INNV

The primary concerns for INNV are Market Cap, Return on Equity, EPS Growth.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

INNV profiles as a growth stock while MRK is a value play — different risk/reward profiles.

MRK carries more volatility with a beta of 0.22 — expect wider price swings.

INNV is growing revenue faster at 18.3% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (44/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

InnovAge Holding Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

InnovAge Holding Corp. The company is headquartered in Denver, Colorado.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?